Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation

PURPOSE: Cetuximab and panitumumab have an effective therapeutic response in a subset of RAS Wild-Type (WT) metastatic colorectal cancers (mCRCs). Despite molecular-driven selection, all patients do not respond to epidermal growth factor receptor (EGFR) inhibitors and the onset of secondary resistan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Napolitano, Stefania, Martini, Giulia, Martinelli, Erika, Belli, Valentina, Parascandolo, Alessia, Laukkanen, Mikko O., Sforza, Vincenzo, Morgillo, Floriana, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620195/
https://ncbi.nlm.nih.gov/pubmed/28978055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18749
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars